{
  "doc_id": "bc419729c80323bfe3e09427842c90ab84c2d9521ecb49170895e21dc4382c10",
  "chunk_entities": [
    {
      "chunk_id": "9a13226fa88cf3341928defbe28910ae",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin",
          "context": "Serotonin signaling"
        },
        {
          "entity_type": "Disease",
          "entity_name": "AD",
          "context": "Serotonin signaling and AD"
        },
        {
          "entity_type": "Effect",
          "entity_name": "influences executive function",
          "context": "influences executive function in humans"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin transporter",
          "context": "serotonin transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT-4",
          "context": "serotonin receptor subtypes (5-HT-4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT-7",
          "context": "serotonin receptor subtypes (5-HT-7)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amyloid precursor protein (APP)",
          "context": "amyloid precursor protein processing (APP)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin receptor type-4",
          "context": "Activation of serotonin receptor type-4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alpha-secretase",
          "context": "upregulates alpha-secretase"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduces the amyloid load",
          "context": "reduces the amyloid load"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improves cognitive deficits",
          "context": "improves cognitive deficits"
        },
        {
          "entity_type": "Compound",
          "entity_name": "selective serotonin reuptake inhibitor (SSRI)",
          "context": "selective serotonin reuptake inhibitor (SSRI)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-depressants",
          "context": "indicated as anti-depressants"
        },
        {
          "entity_type": "Disease",
          "entity_name": "major depression",
          "context": "for major depression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "citaloprim",
          "context": "(citaloprim, fluoxetine)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fluoxetine",
          "context": "(citaloprim, fluoxetine)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduced amyloid plaques",
          "context": "reduced amyloid plaques"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SSRI",
          "context": "exposed to SSRI"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduction in amyloid-beta load",
          "context": "reduction in amyloid-beta load"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amyloid-beta (A\u03b2)",
          "context": "CSF A\u03b2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "link of serotonin activity"
        },
        {
          "entity_type": "Disease",
          "entity_name": "AD",
          "context": "tau pathology in AD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin neurotoxin",
          "context": "serotonin neurotoxin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5,7-Dihydroxytryptamine (5,7HT)",
          "context": "5,7-Dihydroxytryptamine (5,7HT)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increased tau phosphorylation",
          "context": "leads to increased tau phosphorylation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impaired cognitive performance",
          "context": "impaired cognitive performance"
        }
      ]
    },
    {
      "chunk_id": "515e1c3296e5748a619be498360e6485",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "obstructive lung disease",
          "context": "obstructive lung disease"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 holo-enzyme",
          "context": "binds to PDE4 holo-enzyme state of PDE-4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "state of PDE-4"
        },
        {
          "entity_type": "Effect",
          "entity_name": "nausea",
          "context": "side effects of nausea and vomiting"
        },
        {
          "entity_type": "Effect",
          "entity_name": "vomiting",
          "context": "side effects of nausea and vomiting"
        }
      ]
    },
    {
      "chunk_id": "5be1c53c79c532b336aa7a50c48188f3",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "allosteric modulation of PDE-4"
        },
        {
          "entity_type": "Effect",
          "entity_name": "allosteric modulation",
          "context": "allosteric modulation of PDE-4"
        },
        {
          "entity_type": "Effect",
          "entity_name": "competitive inhibition",
          "context": "competitive inhibition of PDE-4"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reducing",
          "context": "for reducing and eliminating the troublesome side effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "eliminating",
          "context": "for reducing and eliminating the troublesome side effects"
        },
        {
          "entity_type": "Disease",
          "entity_name": "nausea",
          "context": "side effects of nausea and vomiting"
        },
        {
          "entity_type": "Disease",
          "entity_name": "vomiting",
          "context": "side effects of nausea and vomiting"
        },
        {
          "entity_type": "Effect",
          "entity_name": "efficacy",
          "context": "in support of the efficacy of rolipram"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "efficacy of rolipram"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "prototypical PDE-4 competitive inhibitor"
        },
        {
          "entity_type": "Disease",
          "entity_name": "depression",
          "context": "trials for depression and AD"
        },
        {
          "entity_type": "Disease",
          "entity_name": "AD",
          "context": "trials for depression and AD"
        },
        {
          "entity_type": "Disease",
          "entity_name": "nausea",
          "context": "side effects of nausea and vomiting"
        },
        {
          "entity_type": "Disease",
          "entity_name": "vomiting",
          "context": "side effects of nausea and vomiting"
        },
        {
          "entity_type": "Effect",
          "entity_name": "allosteric modulator",
          "context": "model of allosteric modulator of PDE-4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "allosteric modulator of PDE-4"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improve tolerability",
          "context": "to improve tolerability"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "pharmacophore of PDE-4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "allosteric PDE-4 modulators"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhance selectivity of therapeutic effects",
          "context": "can enhance selectivity of therapeutic effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "minimizing the side effects",
          "context": "while minimizing the side effects"
        }
      ]
    },
    {
      "chunk_id": "2d0dceae5f75a010f7de36535fe0cf88",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4 allosteric modulators",
          "context": "class of PDE-4 allosteric modulators"
        },
        {
          "entity_type": "Effect",
          "entity_name": "emetic effects",
          "context": "devoid of serious emetic effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "EHT0202",
          "context": "Pipeline drugs : EHT0202"
        },
        {
          "entity_type": "Compound",
          "entity_name": "etiolate hydrochloride",
          "context": "EHT0202 (etiolate hydrochloride)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "L-454,560",
          "context": "L-454,560"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GEBR-7-b",
          "context": "GEBR-7-b"
        },
        {
          "entity_type": "Effect",
          "entity_name": "gastrointestinal side effects",
          "context": "free from serious gastrointestinal side effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "nausea",
          "context": "no nausea"
        },
        {
          "entity_type": "Effect",
          "entity_name": "vomiting",
          "context": "no nausea and vomiting"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Mg2+",
          "context": "apo-(Mg2+-free) and holoenzyme states (Mg2+-bound)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4A",
          "context": "PDE-4A, PDE-B and PDE-D isoforms"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-B",
          "context": "PDE-4A, PDE-B and PDE-D isoforms"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-D",
          "context": "PDE-4A, PDE-B and PDE-D isoforms"
        },
        {
          "entity_type": "Effect",
          "entity_name": "emesis",
          "context": "without producing emesis in vivo"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "derivative of rolipram"
        },
        {
          "entity_type": "Effect",
          "entity_name": "memory tasks",
          "context": "rolipram in memory tasks"
        },
        {
          "entity_type": "Effect",
          "entity_name": "emesis",
          "context": "measures of emesis"
        }
      ]
    },
    {
      "chunk_id": "de7e58ba79cb21e0a445bcb8f16bb12e",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "SSRI",
          "context": "Coupling SSRI with PDE-4 signals"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "Coupling SSRI with PDE-4 signals"
        },
        {
          "entity_type": "Compound",
          "entity_name": "molecule",
          "context": "within the same molecule"
        },
        {
          "entity_type": "Disease",
          "entity_name": "AD",
          "context": "in AD drug development"
        },
        {
          "entity_type": "Compound",
          "entity_name": "compounds",
          "context": "a class of compounds coupling SSRI with PDE-4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitor",
          "context": "The dual PDE4 inhibitor/SSRI"
        },
        {
          "entity_type": "Compound",
          "entity_name": "2-{5-[3-(5-fluoro-2-methoxy-phenyl)-ethyl]-tetrahydro-furan-2-yl}-ethylamine)-pentyl]-4,5,8,8a-tetrahydro-2H-phthalazin-1-one",
          "context": "The dual PDE4 inhibitor/SSRI 2-{5-[3-(5-fluoro-2-methoxy-phenyl)-ethyl]-tetrahydro-furan-2-yl}-ethylamine)-pentyl]-4,5,8,8a-tetrahydro-2H-phthalazin-1-one"
        },
        {
          "entity_type": "Compound",
          "entity_name": "compound 21",
          "context": "phthalazin-1-one (compound 21)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "active in the forced swim test",
          "context": "was active in the forced swim test in mice"
        },
        {
          "entity_type": "Effect",
          "entity_name": "high affinity for SSRI",
          "context": "possessed high affinity for SSRI"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "IC50 127 nM",
          "context": "SSRI : IC50 127 nM"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4D3",
          "context": "and PDE4D3 K9i) value"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "K9i) value of 2.0 nM",
          "context": "PDE4D3 K9i) value of 2.0 nM"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Mesembrine alkaloids",
          "context": "Mesembrine alkaloids represent the first group"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phyto-chemicals",
          "context": "group of phyto-chemicals"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "dually targeting serotonin signaling"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neurotropic effects",
          "context": "for their neurotropic and neurotrophic effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neurotrophic effects",
          "context": "for their neurotropic and neurotrophic effects"
        },
        {
          "entity_type": "Plant",
          "entity_name": "Sceletium tortuosum",
          "context": "from Sceletium tortuosum"
        },
        {
          "entity_type": "Compound",
          "entity_name": "trans-capping conformer",
          "context": "conformation: trans-capping conformer"
        },
        {
          "entity_type": "Effect",
          "entity_name": "partially inhibiting the PDE-4 catalytic domain",
          "context": "partially inhibiting the PDE-4 catalytic domain"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin extract",
          "context": "standardized Zembrin extract"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Phosphokinase A",
          "context": "PDE-4- Phosphokinase A"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PK-A",
          "context": "Phosphokinase A (PK-A)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CREB",
          "context": "PK-A)-CREB signal pathway"
        },
        {
          "entity_type": "Effect",
          "entity_name": "without activating the emesis reflex",
          "context": "without activating the emesis reflex in the area postrema"
        }
      ]
    },
    {
      "chunk_id": "81617c9aa53c458104b0c856da229286",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "studies of Zembrin"
        },
        {
          "entity_type": "Effect",
          "entity_name": "therapeutic potential",
          "context": "likely potential therapeutic potential"
        }
      ]
    },
    {
      "chunk_id": "cec1c5cf0461a8893242486d9c6d10b9",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "pharmacological targets of Zembrin extract"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neurotropic effects",
          "context": "putative neurotropic effects of Zembrin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alkaloids",
          "context": "potencies of alkaloids"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "competing directly for the PDE-4 binding"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4B",
          "context": "human recombinant PDE-4B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4D",
          "context": "human recombinant PDE-4D"
        },
        {
          "entity_type": "Plant",
          "entity_name": "Selenium tortuosum",
          "context": "extract Selenium tortuosum (Zembrin\u00ae)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "Selenium tortuosum (Zembrin\u00ae)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase 4 (PDE4)",
          "context": "selectively inhibited phosphodiesterase 4 (PDE4)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibited phosphodiesterase 4",
          "context": "selectively inhibited phosphodiesterase 4 (PDE4)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "8.5 \u00b5g/ml",
          "context": "IC50 (inhibitory constant) value of 8.5 \u00b5g/ml"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mesembrenone",
          "context": "mesembrenone is the most potent compound"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4B",
          "context": "in inhibiting PDE-4B"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibiting PDE-4B",
          "context": "most potent compound in inhibiting PDE-4B"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4",
          "context": "recombinant PDE4 in vitro assay"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Mesembrenone",
          "context": "Mesembrenone, a major alkaloid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alkaloid",
          "context": "Mesembrenone, a major alkaloid"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibiting PDE4",
          "context": "active in inhibiting PDE4"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "< 1\u00b5M",
          "context": "IC50 value of < 1\u00b5M"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Mesembrenone",
          "context": "Mesembrenone was 17 times more potent"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mesembrine",
          "context": "more potent than mesembrine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mesembrenol",
          "context": "more active than mesembrenol"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "competing for PDE-4 binding"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mesembrenone",
          "context": "IC50 values for mesembrenone"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "470 nM",
          "context": "was 470 nM"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mesembrine",
          "context": "followed by mesembrine"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "7800 nM",
          "context": "7800 nM"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mesembrenol",
          "context": "mesembrenol: 10,000 nM"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "10,000 nM",
          "context": "10,000 nM"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pharmacological effects",
          "context": "pharmacological effects of Zembrin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "pharmacological effects of Zembrin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mesembrine alkaloids",
          "context": "mesembrine alkaloids are mediated"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4D3",
          "context": "isoform of PDE-4D3"
        },
        {
          "entity_type": "Plant",
          "entity_name": "Selenium tortuosum",
          "context": "extract Selenium tortuosum (Zembrin\u00ae)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "Selenium tortuosum (Zembrin\u00ae)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GABA receptor",
          "context": "activities at the GABA receptor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mu (\u00b5) opioid receptors",
          "context": "mu (\u00b5) and delta (\u03b42) opioid receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "delta (\u03b42) opioid receptors",
          "context": "delta (\u03b42) opioid receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cholecystokinin-1",
          "context": "cholecystokinin-1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "EP4 prostaglandin",
          "context": "EP4 prostaglandin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "melatonin-1 receptors",
          "context": "melatonin-1 receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "less than that of PDE-4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT uptake sites",
          "context": "5-HT uptake sites"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "PDE-4 interaction with Zembrin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "standardized Zembrin extract"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mesembrane related alkaloids",
          "context": "mesembrane related alkaloids exhibited little effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-1",
          "context": "effects on PDE-1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-2",
          "context": "PDE-2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-3",
          "context": "PDE-3"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-5",
          "context": "PDE-5"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-6",
          "context": "PDE-6"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-7",
          "context": "PDE-7"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-8",
          "context": "PDE-8"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-10",
          "context": "PDE-10"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-11a",
          "context": "PDE-11a"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "roflumilast (Daliresp, Forest Pharmaceuticals)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase-4 (PDE-4)",
          "context": "oral phosphodiesterase-4 (PDE-4) inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibitor",
          "context": "phosphodiesterase-4 (PDE-4) inhibitor"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease (COPD)",
          "context": "triggering chronic obstructive pulmonary disease (COPD) exacerbation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "Whether Zembrin behaves similarly"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "clinical studies of Zembrin"
        },
        {
          "entity_type": "Effect",
          "entity_name": "adverse effects",
          "context": "do not find any adverse effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Mesembrine alkaloids",
          "context": "Mesembrine alkaloids are distinguished"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4 inhibitors",
          "context": "classical PDE-4 inhibitors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "serotonergic activity",
          "context": "displaying concomitant serotonergic activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Mesembrine",
          "context": "Mesembrine was found to be the most potent compound"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin transporter site (5-HT site)",
          "context": "binding to the serotonin transporter site (5-HT site)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT site",
          "context": "serotonin transporter site (5-HT site)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.4 nM",
          "context": "Hill coefficient of 1.4 nM"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Mesembrenone",
          "context": "Mesembrenone and mesembranol are less potent"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mesembranol",
          "context": "Mesembrenone and mesembranol"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT transport site",
          "context": "competing for the 5-HT transport site"
        }
      ]
    },
    {
      "chunk_id": "309d84066aa0d8e211697b4fbef9613a",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "Zembrin effects on symptoms"
        },
        {
          "entity_type": "Disease",
          "entity_name": "canine cognitive dysfunction (CCD)",
          "context": "symptoms of canine cognitive dysfunction (CCD)"
        },
        {
          "entity_type": "Disease",
          "entity_name": "feline cognitive dysfunction (FCD)",
          "context": "feline cognitive dysfunction (FCD )"
        },
        {
          "entity_type": "Disease",
          "entity_name": "AD",
          "context": "mirroring AD in humans"
        },
        {
          "entity_type": "Disease",
          "entity_name": "dementia",
          "context": "core signs of dementia"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "mix the Zembrin capsules"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "2 mg/kg",
          "context": "from 2 mg/kg"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "90 mg/kg oral dosage",
          "context": "maximum of 90 mg/kg oral dosage"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "30 mg/kg oral daily",
          "context": "minimum effective dosage was 30 mg/kg oral daily"
        },
        {
          "entity_type": "Effect",
          "entity_name": "fast onset of action",
          "context": "fast onset of action within he first 30 minutes"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dose-dependent",
          "context": "The response was dose-dependent."
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "response rate of Zembrin"
        },
        {
          "entity_type": "Effect",
          "entity_name": "markedly effective",
          "context": "8/33 markedly effective"
        },
        {
          "entity_type": "Effect",
          "entity_name": "moderately effective",
          "context": "12/33 moderately effective"
        },
        {
          "entity_type": "Effect",
          "entity_name": "minimally effective",
          "context": "12/33 minimally effective"
        },
        {
          "entity_type": "Disease",
          "entity_name": "dementia",
          "context": "baseline dementia score"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "Zembrin was highly tolerable"
        },
        {
          "entity_type": "Effect",
          "entity_name": "highly tolerable",
          "context": "Zembrin was highly tolerable"
        },
        {
          "entity_type": "Disease",
          "entity_name": "nausea",
          "context": "no complaint of nausea"
        },
        {
          "entity_type": "Disease",
          "entity_name": "vomiting",
          "context": "or vomiting"
        }
      ]
    },
    {
      "chunk_id": "d08afb40921763b65070ba0549a5d4a9",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "standardized Zembrin extract"
        },
        {
          "entity_type": "Effect",
          "entity_name": "centrally active in cognition",
          "context": "centrally active in cognition"
        },
        {
          "entity_type": "Effect",
          "entity_name": "memory",
          "context": "cognition , memory"
        },
        {
          "entity_type": "Effect",
          "entity_name": "affective responses",
          "context": "memory and affective responses"
        },
        {
          "entity_type": "Effect",
          "entity_name": "safe",
          "context": "to be safe"
        },
        {
          "entity_type": "Effect",
          "entity_name": "free from adverse events",
          "context": "free from adverse events"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "Zembrin passes through the BBB"
        },
        {
          "entity_type": "Effect",
          "entity_name": "passes through the BBB (Blood-Brain Barrier)",
          "context": "Zembrin passes through the BBB (Blood-Brain Barrier)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "modify the functional responses towards environmental cues capable of generating fear",
          "context": "modify the functional responses towards environmental cues capable of generating fear"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemical moiety",
          "context": "a chemical moiety can penetrate the BBB"
        },
        {
          "entity_type": "Effect",
          "entity_name": "penetrate the BBB",
          "context": "can penetrate the BBB"
        },
        {
          "entity_type": "Effect",
          "entity_name": "produce the brain activation responses",
          "context": "produce the brain activation responses"
        },
        {
          "entity_type": "Effect",
          "entity_name": "attenuated",
          "context": "reactivity of amygdala to fearful faces under low perceptual load conditions was attenuated"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "25 mg oral dose",
          "context": "a single 25 mg oral dose"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "Zembrin attenuated the emotional responses"
        },
        {
          "entity_type": "Effect",
          "entity_name": "attenuated the emotional responses",
          "context": "Zembrin attenuated the emotional responses"
        },
        {
          "entity_type": "Effect",
          "entity_name": "adversely affected",
          "context": "amygdala-hypothalamus coupling was adversely affected"
        },
        {
          "entity_type": "Effect",
          "entity_name": "emotional memory changes",
          "context": "emotional memory changes localized to medial temporal lobe"
        },
        {
          "entity_type": "Disease",
          "entity_name": "AD",
          "context": "medial temporal lobe in AD"
        }
      ]
    },
    {
      "chunk_id": "30a59883e10cb22e75e64673a8bd011a",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "Alzheimer dementia",
          "context": "earliest stage of Alzheimer dementia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impairment in executive functioning",
          "context": "impairment in executive functioning is present"
        },
        {
          "entity_type": "Effect",
          "entity_name": "memory deficits",
          "context": "before marked memory deficits appear"
        },
        {
          "entity_type": "Disease",
          "entity_name": "mild cognitive impairment",
          "context": "mild cognitive impairment (MCI)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impaired instrumental activities of daily living",
          "context": "impaired instrumental activities of daily living predicting cognitive decline"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cognitive decline",
          "context": "predicting cognitive decline"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cognitive enhancing effect",
          "context": "The cognitive enhancing effect of Zembrin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "effect of Zembrin in humans"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin extract",
          "context": "effect of Zembrin extract in the Morris water maze test"
        }
      ]
    },
    {
      "chunk_id": "1e0268f62c7dabbb2312a1fcd617a8a3",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "earlier study of Zembrin"
        },
        {
          "entity_type": "Effect",
          "entity_name": "generalized well-being",
          "context": "subjective ratings of generalized well-being"
        },
        {
          "entity_type": "Effect",
          "entity_name": "positive mood states",
          "context": "subjective ratings of ... positive mood states"
        },
        {
          "entity_type": "Effect",
          "entity_name": "uplifted spirits",
          "context": "reported \"uplifted spirits\""
        },
        {
          "entity_type": "Effect",
          "entity_name": "better coping with stress",
          "context": "better coping with stress"
        },
        {
          "entity_type": "Effect",
          "entity_name": "better coping with depressing events",
          "context": "better coping with ... depressing events"
        },
        {
          "entity_type": "Disease",
          "entity_name": "stress",
          "context": "coping with stress"
        },
        {
          "entity_type": "Disease",
          "entity_name": "depressing events",
          "context": "coping with ... depressing events"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "subjects taking Zembrin\u00ae"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improvement in the subjective quality of their sleep",
          "context": "reported improvement in the subjective quality of their sleep"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "effects of Zembrin on mood and sleep"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "function of PDE-4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SSRI",
          "context": "function of ... SSRI"
        },
        {
          "entity_type": "Effect",
          "entity_name": "regulating mood",
          "context": "in regulating mood"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhancing cognition",
          "context": "enhancing cognition"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improving sleep quality",
          "context": "improving sleep quality"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "Zembrin treated group"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improvement in sleep",
          "context": "found an overall improvement in sleep"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "studies on PDE-4 in sleep regulation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "sleep regulation",
          "context": "PDE-4 in sleep regulation"
        },
        {
          "entity_type": "Disease",
          "entity_name": "sleep deprivation",
          "context": "In sleep deprivation model"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "5 hours",
          "context": "sleep deprived for 5 hours"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cAMP",
          "context": "impairment in cAMP/phosphokinase A-dependent synaptic plasticity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphokinase A",
          "context": "cAMP/phosphokinase A-dependent synaptic plasticity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impairment in cAMP/phosphokinase A-dependent synaptic plasticity",
          "context": "showed selective impairment in cAMP/phosphokinase A-dependent synaptic plasticity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "long-term potentiation (LTP)",
          "context": "long-term potentiation (LTP) paradigm"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4 inhibitor",
          "context": "Treatment with PDE-4 inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "rolipram",
          "context": "PDE-4 inhibitor, rolipram"
        },
        {
          "entity_type": "Effect",
          "entity_name": "restored sleep loss",
          "context": "restored both sleep loss"
        },
        {
          "entity_type": "Disease",
          "entity_name": "sleep loss",
          "context": "restored both sleep loss"
        },
        {
          "entity_type": "Effect",
          "entity_name": "restored LTP deficits",
          "context": "restored both ... LTP deficits"
        },
        {
          "entity_type": "Disease",
          "entity_name": "LTP deficits",
          "context": "restored both ... LTP deficits"
        },
        {
          "entity_type": "Disease",
          "entity_name": "sleep deprivation",
          "context": "sleep deprivation attenuates cAMP signaling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cAMP",
          "context": "attenuates cAMP signaling"
        },
        {
          "entity_type": "Effect",
          "entity_name": "attenuates cAMP signaling",
          "context": "attenuates cAMP signaling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CREB",
          "context": "CREB-mediated gene expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "attenuates CREB-mediated gene expression",
          "context": "attenuates ... CREB-mediated gene expression"
        }
      ]
    },
    {
      "chunk_id": "c98538d3476534121c84dba0e8e1052d",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "Zembrin at oral dosage of 25 mg"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "25 mg",
          "context": "oral dosage of 25 mg"
        },
        {
          "entity_type": "Effect",
          "entity_name": "safe",
          "context": "was safe and well tolerated"
        },
        {
          "entity_type": "Effect",
          "entity_name": "well tolerated",
          "context": "was safe and well tolerated"
        },
        {
          "entity_type": "Effect",
          "entity_name": "nausea",
          "context": "no nausea or vomiting"
        },
        {
          "entity_type": "Effect",
          "entity_name": "vomiting",
          "context": "no nausea or vomiting"
        },
        {
          "entity_type": "Effect",
          "entity_name": "abnormalities",
          "context": "No abnormalities were found"
        },
        {
          "entity_type": "Effect",
          "entity_name": "metabolic parameters",
          "context": "metabolic parameters (lipid, fasting glucose, electrolytes)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "liver and kidney functions",
          "context": "liver and kidney functions"
        },
        {
          "entity_type": "Effect",
          "entity_name": "heightened sense of well-being",
          "context": "reported a heightened sense of well-being"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cope with stress",
          "context": "felt better to cope with stress"
        },
        {
          "entity_type": "Effect",
          "entity_name": "euphoria",
          "context": "no euphoria occurred"
        },
        {
          "entity_type": "Effect",
          "entity_name": "abuse liability",
          "context": "No euphoria or abuse liability was found"
        },
        {
          "entity_type": "Effect",
          "entity_name": "metabolic side effects",
          "context": "No metabolic side effects were seen"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin extract",
          "context": "studies of Zembrin extract"
        },
        {
          "entity_type": "Effect",
          "entity_name": "QT-prolongation effect",
          "context": "No QT-prolongation effect was observed"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SSRI",
          "context": "targeting SSRI"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "PDE-4/PKA/CREB"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PKA",
          "context": "PDE-4/PKA/CREB"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CREB",
          "context": "PDE-4/PKA/CREB"
        },
        {
          "entity_type": "Compound",
          "entity_name": "HAT",
          "context": "epigenetic signature HAT"
        },
        {
          "entity_type": "Disease",
          "entity_name": "major depression disorder",
          "context": "diagnosed as major depression disorder"
        },
        {
          "entity_type": "Disease",
          "entity_name": "dysthymia",
          "context": "dysthymia with co-morbid personality disorder"
        },
        {
          "entity_type": "Disease",
          "entity_name": "personality disorder",
          "context": "co-morbid personality disorder"
        },
        {
          "entity_type": "Disease",
          "entity_name": "major depressive disorder",
          "context": "and major depressive disorder"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "Zembrin at 50 mg po"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "50 mg",
          "context": "Zembrin at 50 mg po"
        },
        {
          "entity_type": "Effect",
          "entity_name": "efficacious",
          "context": "was efficacious in improving depressive symptoms"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improving depressive symptoms",
          "context": "efficacious in improving depressive symptoms"
        },
        {
          "entity_type": "Disease",
          "entity_name": "sleep disturbances",
          "context": "depressive symptoms: sleep disturbances"
        },
        {
          "entity_type": "Disease",
          "entity_name": "anxiety",
          "context": "sleep disturbances, anxiety and concentration difficulties"
        },
        {
          "entity_type": "Disease",
          "entity_name": "concentration difficulties",
          "context": "anxiety and concentration difficulties"
        },
        {
          "entity_type": "Disease",
          "entity_name": "hypersomnia",
          "context": "hypersomnia was resolved"
        }
      ]
    },
    {
      "chunk_id": "1993f63ecc8b84852992e4f8f6af598e",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Sildenafil",
          "context": "Sildenafil and tadalafil, the putative PDE-5 inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tadalafil",
          "context": "Sildenafil and tadalafil, the putative PDE-5 inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-5 inhibitors",
          "context": "the putative PDE-5 inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cGMP",
          "context": "act through cGMP system"
        },
        {
          "entity_type": "Disease",
          "entity_name": "erectile dysfunction",
          "context": "are indicated for erectile dysfunction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "AD",
          "context": "for AD treatment"
        },
        {
          "entity_type": "Disease",
          "entity_name": "melanoma",
          "context": "increased incidence of melanoma"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin",
          "context": "Zembrin had no effect"
        },
        {
          "entity_type": "Effect",
          "entity_name": "no effect on growth",
          "context": "had no effect on growth"
        },
        {
          "entity_type": "Effect",
          "entity_name": "no effect on viability",
          "context": "or viability"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "24-hr exposure",
          "context": "following 24-hr exposure"
        }
      ]
    },
    {
      "chunk_id": "e484e994305f0d71b634f23510c6e179",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Zembrin extract",
          "context": "proprietary Zembrin extract"
        }
      ]
    },
    {
      "chunk_id": "ade9c1031cd017c58f7ac59279ef9ec1",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "GSK3\u03b2",
          "context": "GSK3\u03b2, CREB, and BDNF in peripheral blood"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CREB",
          "context": "GSK3\u03b2, CREB, and BDNF in peripheral blood"
        },
        {
          "entity_type": "Compound",
          "entity_name": "BDNF",
          "context": "GSK3\u03b2, CREB, and BDNF in peripheral blood"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Alzheimer's disease",
          "context": "patients with Alzheimer's disease and depression"
        },
        {
          "entity_type": "Disease",
          "entity_name": "depression",
          "context": "patients with Alzheimer's disease and depression"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Alzheimer Disease",
          "context": "Neurogenesis and Alzheimer Disease"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cytokines",
          "context": "Role of Cytokines ScientificWorldJournal"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Alzheimer's Disease",
          "context": "Inflammatory Process in Alzheimer's Disease"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "Update on roflumilast, a phosphodiesterase 4 inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase 4 inhibitor",
          "context": "roflumilast, a phosphodiesterase 4 inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "treatment",
          "context": "for the treatment of chronic obstructive pulmonary disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "treatment of chronic obstructive pulmonary disease"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Proinflammatory",
          "context": "Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cyclic AMP-phosphodiesterase 4",
          "context": "Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cyclic AMP-specific phosphodiesterase-4",
          "context": "Cyclic AMP-specific phosphodiesterase-4 as a target"
        },
        {
          "entity_type": "Effect",
          "entity_name": "antidepressant",
          "context": "development of antidepressant drugs"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Pde4d",
          "context": "A new model of Pde4d deficiency"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4D enzyme",
          "context": "knock-down of PDE4D enzyme in rats"
        },
        {
          "entity_type": "Effect",
          "entity_name": "antidepressant phenotype",
          "context": "produces an antidepressant phenotype"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Antidepressants",
          "context": "Antidepressants for neuro-regeneration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuro-regeneration",
          "context": "Antidepressants for neuro-regeneration"
        },
        {
          "entity_type": "Disease",
          "entity_name": "depression",
          "context": "from depression to Alzheimer's disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Alzheimer's disease",
          "context": "from depression to Alzheimer's disease"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase type IV",
          "context": "brain phosphodiesterase type IV measured with 11C-(R)-rolipram"
        },
        {
          "entity_type": "Compound",
          "entity_name": "11C-(R)-rolipram",
          "context": "measured with 11C-(R)-rolipram positron emission tomography"
        },
        {
          "entity_type": "Disease",
          "entity_name": "major depressive disorder",
          "context": "in major depressive disorder"
        },
        {
          "entity_type": "Compound",
          "entity_name": "noradrenaline",
          "context": "Increasing synaptic noradrenaline, serotonin and histamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "synaptic noradrenaline, serotonin and histamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "histamine",
          "context": "serotonin and histamine enhances in vivo binding"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase-4 inhibitor",
          "context": "binding of phosphodiesterase-4 inhibitor (R)-[11C]rolipram"
        },
        {
          "entity_type": "Compound",
          "entity_name": "(R)-[11C]rolipram",
          "context": "phosphodiesterase-4 inhibitor (R)-[11C]rolipram in rat brain"
        },
        {
          "entity_type": "Compound",
          "entity_name": "hypocretin",
          "context": "role of hypocretin and melatonin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "melatonin",
          "context": "role of hypocretin and melatonin"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Alzheimer's disease",
          "context": "circadian rhythms and Alzheimer's disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "mental Health Problems",
          "context": "Sleep disturbances in mental Health Problems and neurodegenerative disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neurodegenerative disorders",
          "context": "mental Health Problems and neurodegenerative disorders"
        }
      ]
    },
    {
      "chunk_id": "bb4bd90f7336366bb7e4e6f52b87adfc",
      "entities": [
        {
          "entity_type": "Plant",
          "entity_name": "Sceletium tortuosum",
          "context": "Extract Sceletium tortuosum (Zembrin)"
        },
        {
          "entity_type": "Plant",
          "entity_name": "Sceletium tortuosum",
          "context": "standardized Zembrin extract"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mesembrenone",
          "context": "mesembrenone targeting PDE-4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-4",
          "context": "targeting PDE-4 (Phosphodiesterase subtype 4)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Phosphodiesterase subtype 4",
          "context": "PDE-4 (Phosphodiesterase subtype 4)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "regulation of Mood",
          "context": "for regulation of Mood and Cognition"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Cognition",
          "context": "for regulation of Mood and Cognition"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Sildenafil",
          "context": "Sildenafil use and increased risk"
        },
        {
          "entity_type": "Disease",
          "entity_name": "melanoma",
          "context": "incident melanoma in US men"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Cognitive",
          "context": "Cognitive tests used in chronic adult human"
        },
        {
          "entity_type": "Compound",
          "entity_name": "micronutrient",
          "context": "micronutrient and phytochemical intervention studies"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phytochemical",
          "context": "micronutrient and phytochemical intervention studies"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Alzheimer's disease",
          "context": "markers for Alzheimer's disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "MCI",
          "context": "at the prodromal (MCI) stage"
        },
        {
          "entity_type": "Disease",
          "entity_name": "mild cognitive impairment",
          "context": "conversion from mild cognitive impairment to Alzheimer disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Alzheimer disease",
          "context": "impairment to Alzheimer disease"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cognitive",
          "context": "cognitive markers, and risk factors"
        }
      ]
    }
  ],
  "total_entities": 352,
  "extraction_date": "2026-02-01T08:37:34.387249+00:00"
}